Polycythemia: from clones to clinic.
Increasing evidence for pathological erythroid clones and availability of additional diagnostic criteria suggest to reconsider the classification of polycythemia, with particular regard to the separation between primary proliferative polycythemia (PPP) or polycythemia vera, and other conditions in which the excessive red cell mass is not due to a myeloproliferative disorder. The characteristics of the abnormal erythropoietic clone in PPP are reviewed, with special reference to the in vitro growth of Epo-independent clones and the response to Epo and other growth factors. Traditional PPP diagnostic criteria are thus integrated with more recent parameters and the clinical features are considered; the main features of idiopathic erythrocytosis (IE) are also reviewed, as well as those of other forms, like familial, secondary and apparent polycythemia. It is pointed out that previously obscure forms are now being elucidated, with the decisive help from molecular biology investigations, allowing the discovery of genetic defects. It is thus becoming apparent that basic science acquisitions, as in the field of erythropoietic initiators (Epo receptor, GATA-1 transcription factor and so on) are eventually helping our understanding of clinical problems in this area, with relevant consequences on diagnosis and treatment of various forms of polycythemia.